Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Ars Pharmaceuticals Inc (SPRY) Insider Trading Activity
Healthcare • Biotechnology • 23 employees
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Total Value
-$31,210,034.13
Total Shares
-1,388,188
Average Trade Value
-$410,658.34
Most Active Insider
Flynn James E
Total Activity: $10,143,706
Largest Single Transaction
$4,058,921
by Flynn James E on Nov 11, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
| Feb 3, 2025 | 50,000 | $615,565 | 210,346 (-23.8%) | Sale | ||
| Feb 3, 2025 | 9,064 | $28,552 | 219,410 (+4.1%) | Exercise/Conversion | ||
| Feb 3, 2025 | 40,936 | $198,540 | 260,346 (+15.7%) | Exercise/Conversion | ||
| Jan 6, 2025 | 50,000 | $555,065 | 210,346 (-23.8%) | Sale | ||
| Jan 6, 2025 | 50,000 | $157,500 | 260,346 (+19.2%) | Exercise/Conversion | ||
|
President and CEO
|
Dec 17, 2024 | 50,000 | $583,575 | 1,297,447 (-3.9%) | Sale | |
|
President and CEO
|
Dec 17, 2024 | 50,000 | $583,525 | 1,098,499 (-4.6%) | Sale | |
|
Chief Medical Officer
|
Dec 17, 2024 | 50,000 | $583,525 | 1,098,499 (-4.6%) | Sale | |
|
Chief Medical Officer
|
Dec 17, 2024 | 50,000 | $583,575 | 1,297,447 (-3.9%) | Sale | |
|
Chief Business Officer
|
Dec 13, 2024 | 27,272 | $328,969 | 136,380 (-20.0%) | Sale | |
|
Chief Business Officer
|
Dec 13, 2024 | 27,272 | $39,272 | 163,652 (+16.7%) | Exercise/Conversion | |
|
Chief Business Officer
|
Dec 12, 2024 | 117,333 | $1,439,124 | 136,380 (-86.0%) | Sale | |
|
Chief Business Officer
|
Dec 12, 2024 | 117,333 | $98,560 | 253,713 (+46.2%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Dec 12, 2024 | 25,000 | $16,000 | 31,024 (+80.6%) | Exercise/Conversion | |
|
Chief Operating Officer
|
Dec 12, 2024 | 25,000 | $307,433 | 6,024 (-415.0%) | Sale | |
|
Chief Operating Officer
|
Dec 11, 2024 | 15,000 | $186,426 | 6,024 (-249.0%) | Sale | |
|
Chief Operating Officer
|
Dec 11, 2024 | 15,000 | $9,600 | 21,024 (+71.3%) | Exercise/Conversion | |
|
President and CEO
|
Dec 10, 2024 | 50,000 | $658,155 | 1,148,499 (-4.4%) | Sale | |
|
Chief Business Officer
|
Dec 10, 2024 | 50,000 | $657,625 | 136,380 (-36.7%) | Sale | |
|
Chief Business Officer
|
Dec 10, 2024 | 50,000 | $42,000 | 186,380 (+26.8%) | Exercise/Conversion | |
|
Chief Medical Officer
|
Dec 10, 2024 | 50,000 | $658,155 | 1,148,499 (-4.4%) | Sale | |
|
Chief Medical Officer
|
Dec 10, 2024 | 50,000 | $658,265 | 1,246,494 (-4.0%) | Sale | |
|
President and CEO
|
Dec 10, 2024 | 50,000 | $658,265 | 1,246,494 (-4.0%) | Sale | |
|
President and CEO
|
Dec 6, 2024 | 13,789 | $19,856 | 3,421,636 (+0.4%) | Exercise/Conversion | |
|
President and CEO
|
Dec 6, 2024 | 11,876 | $99,996 | 3,433,512 (+0.3%) | Exercise/Conversion | |
|
Chief Medical Officer
|
Dec 6, 2024 | 11,876 | $99,996 | 3,433,512 (+0.3%) | Exercise/Conversion | |
|
President and CEO
|
Dec 6, 2024 | 11,876 | $99,996 | 4,327,189 (+0.3%) | Exercise/Conversion | |
|
Chief Business Officer
|
Dec 6, 2024 | 50,000 | $711,615 | 136,380 (-36.7%) | Sale | |
|
Chief Business Officer
|
Dec 6, 2024 | 50,000 | $42,000 | 186,380 (+26.8%) | Exercise/Conversion | |
|
Chief Medical Officer
|
Dec 6, 2024 | 13,789 | $19,856 | 3,421,636 (+0.4%) | Exercise/Conversion | |
|
Chief Medical Officer
|
Dec 6, 2024 | 11,876 | $99,996 | 4,327,189 (+0.3%) | Exercise/Conversion | |
|
Chief Business Officer
|
Dec 5, 2024 | 49,640 | $701,642 | 136,380 (-36.4%) | Sale | |
|
Chief Business Officer
|
Dec 5, 2024 | 49,640 | $41,698 | 186,020 (+26.7%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Dec 4, 2024 | 6,283 | $87,962 | 5,693 (-110.4%) | Sale | |
|
Chief Business Officer
|
Dec 4, 2024 | 45,000 | $37,800 | 181,380 (+24.8%) | Exercise/Conversion | |
|
Chief Business Officer
|
Dec 4, 2024 | 45,000 | $627,944 | 136,380 (-33.0%) | Sale | |
| Dec 4, 2024 | 14,772 | $203,109 | 210,346 (-7.0%) | Sale | ||
| Dec 4, 2024 | 14,772 | $46,532 | 225,118 (+6.6%) | Exercise/Conversion | ||
|
Chief Commercial Officer
|
Dec 4, 2024 | 6,283 | $9,425 | 11,976 (+52.5%) | Exercise/Conversion | |
|
Chief Business Officer
|
Dec 3, 2024 | 3,260 | $2,738 | 139,640 (+2.3%) | Exercise/Conversion | |
|
Chief Business Officer
|
Dec 3, 2024 | 41,740 | $35,062 | 181,380 (+23.0%) | Exercise/Conversion | |
|
Chief Business Officer
|
Dec 3, 2024 | 45,000 | $593,402 | 136,380 (-33.0%) | Sale | |
| Dec 3, 2024 | 87,984 | $1,166,897 | 210,346 (-41.8%) | Sale | ||
| Dec 3, 2024 | 25,606 | $32,520 | 235,952 (+10.9%) | Exercise/Conversion | ||
| Dec 3, 2024 | 62,378 | $196,491 | 298,330 (+20.9%) | Exercise/Conversion | ||
|
Chief Business Officer
|
Dec 2, 2024 | 45,000 | $615,218 | 136,380 (-33.0%) | Sale | |
| Dec 2, 2024 | 901 | $12,922 | 210,346 (-0.4%) | Sale | ||
|
Chief Commercial Officer
|
Dec 2, 2024 | 3,717 | $5,576 | 9,410 (+39.5%) | Exercise/Conversion | |
| Dec 2, 2024 | 67,616 | $85,872 | 277,962 (+24.3%) | Exercise/Conversion | ||
| Dec 2, 2024 | 96,343 | $1,305,823 | 211,247 (-45.6%) | Sale | ||
|
Chief Commercial Officer
|
Dec 2, 2024 | 3,717 | $52,461 | 5,693 (-65.3%) | Sale | |
| Dec 2, 2024 | 29,628 | $37,628 | 307,590 (+9.6%) | Exercise/Conversion | ||
|
Chief Business Officer
|
Dec 2, 2024 | 45,000 | $37,800 | 181,380 (+24.8%) | Exercise/Conversion | |
|
Chief Business Officer
|
Nov 27, 2024 | 25,000 | $359,750 | 136,380 (-18.3%) | Sale | |
|
Chief Business Officer
|
Nov 26, 2024 | 42,186 | $592,570 | 161,380 (-26.1%) | Sale | |
|
Chief Business Officer
|
Nov 25, 2024 | 32,814 | $459,422 | 203,566 (-16.1%) | Sale | |
|
Chief Medical Officer
|
Nov 19, 2024 | 50,000 | $697,510 | 1,347,447 (-3.7%) | Sale | |
|
President and CEO
|
Nov 19, 2024 | 50,000 | $697,450 | 1,198,499 (-4.2%) | Sale | |
|
Chief Medical Officer
|
Nov 19, 2024 | 50,000 | $697,450 | 1,198,499 (-4.2%) | Sale | |
|
President and CEO
|
Nov 19, 2024 | 50,000 | $697,510 | 1,347,447 (-3.7%) | Sale | |
|
Chief Medical Officer
|
Nov 12, 2024 | 4,876 | $86,020 | 1,248,499 (-0.4%) | Sale | |
|
Chief Medical Officer
|
Nov 12, 2024 | 45,124 | $756,296 | 1,253,375 (-3.6%) | Sale | |
|
Chief Medical Officer
|
Nov 12, 2024 | 4,955 | $87,421 | 1,296,494 (-0.4%) | Sale | |
|
Chief Medical Officer
|
Nov 12, 2024 | 45,045 | $754,905 | 1,301,449 (-3.5%) | Sale | |
|
10% Owner
|
Nov 12, 2024 | 7,853 | $134,757 | 5,266,883 (-0.1%) | Sale | |
|
10% Owner
|
Nov 12, 2024 | 9,554 | $169,775 | 5,257,329 (-0.2%) | Sale | |
|
President and CEO
|
Nov 12, 2024 | 4,876 | $86,020 | 1,248,499 (-0.4%) | Sale | |
|
10% Owner
|
Nov 12, 2024 | 7,854 | $134,775 | 5,266,881 (-0.1%) | Sale | |
|
President and CEO
|
Nov 12, 2024 | 45,124 | $756,296 | 1,253,375 (-3.6%) | Sale | |
|
President and CEO
|
Nov 12, 2024 | 4,955 | $87,421 | 1,296,494 (-0.4%) | Sale | |
|
10% Owner
|
Nov 12, 2024 | 9,553 | $169,757 | 5,257,328 (-0.2%) | Sale | |
|
President and CEO
|
Nov 12, 2024 | 45,045 | $754,905 | 1,301,449 (-3.5%) | Sale | |
|
10% Owner
|
Nov 11, 2024 | 223,632 | $4,058,921 | 5,274,735 (-4.2%) | Sale | |
|
10% Owner
|
Nov 11, 2024 | 223,632 | $4,058,921 | 5,274,736 (-4.2%) | Sale | |
|
10% Owner
|
Nov 11, 2024 | 40,596 | $708,400 | 5,498,367 (-0.7%) | Sale | |
|
10% Owner
|
Nov 11, 2024 | 40,596 | $708,400 | 5,498,368 (-0.7%) | Sale |